Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline is an orally... Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist.
- Mechanism
- Curator reviewed
Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. Kappa opioid receptors are found mostly in the digestive tract and are believed to play an important role in control of visceral pain and bowel motility. As such, kappa opioid agonists are ideal candidates to relieve the pain, discomfort an impaired motility common to IBS and other gastrointestinal disorders.
- Primary indication
- Investigated for use/treatment in irritable bowel syndrome (IBS).Curator reviewed
- Formula / weight
- C27H30N2O2 · 414.5393 g/mol (avg)
- Code names
- EMD 61753
Resolves to
JHLHNYVMZCADTC-LOSJGSFVSA-NSMILESCN([C@H](CN1CC[C@H](O)C1)C1=CC=CC=C1)C(=O)C(C1=CC=CC=C1)C1=CC=CC=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Asimadoline, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account